A Pipeline in a Product: Haduvio™

Trevi is developing the investigational therapy Haduvio™ (nalbuphine ER) in a range of indications for which patients have few treatment options. With its dual mechanism of action, acting as both an antagonist (blocker) to the mu opioid receptor and as an agonist (activator) to the kappa opioid receptor, Haduvio has the potential to significantly improve the quality of life of patients suffering from serious neurologically mediated conditions by targeting the central and peripheral nervous systems.

We are conducting a global clinical development program for Haduvio™.

Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF)

IPF is a rare, chronic, progressive lung disease, characterized by scarring and thickening of lung tissue; most patients diagnosed with IPF suffer from a dry, non-productive chronic cough that interrupts their daily living and significantly contributes to poor quality of life.

We are conducting a Phase 2 clinical trial of Haduvio for chronic cough in patients with IPF. The Phase 2 trial is a randomized, double-blind, placebo controlled, two-treatment, two-period, crossover study designed to evaluate the efficacy, safety, tolerability and dosing of Haduvio for chronic cough in up to 56 patients with IPF in the United Kingdom.


scientific and clinical
posters & publications

Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications

Elmariah et al., Journal of the American Academy of Dermatology (JAAD) International (2021)

The Role of Kappa- and Mu- Opioid Receptors in Pruritus

as presented at Maui Derm for Dermatologists 2021

Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis

Ständer et al., The American Academy of Dermatology (JAAD) International (2020)

Prevalence of Prurigo Nodularis in Poland

Reich and Ryczek, Acta Dermato Venereologica (2020)

Nalbuphine attenuates itch in the substance P-induced mouse model

as presented at 7th World Congress on Itch (2013).


Trevi Therapeutics

195 Church Street, 14th Floor
New Haven, CT 06510

(203) 304-2499
email us